During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

Signs of multiple sclerosis may surface years before diagnosis, as patients use healthcare more often for early symptoms.

Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are pleased to share data at this year’s ACTRIMS annual meeting, including updates from the ENABLE real world study ...

Some MS diets may help lower inflammation marker levels, but evidence from clinical trials remains limited, according to a new review paper.

The difficulty is that EBV lives latently in B cells in the blood at a frequency, in most immunocompetent individuals, of about 1 in 100,000 to 1 in a million. That level of infection is below the ...

Roche's experimental drug fenebrutinib achieved significant results in a Phase III trial for primary progressive multiple sclerosis (PPMS), reducing the risk of disability progression by 12%. This ...

BERLIN, Feb 7 () - Swiss pharmaceutical company Roche said on Saturday its experimental ​multiple sclerosis drug fenebrutinib ...

—Using CDC data, researchers in Pakistan have found that annual age-adjusted mortality rates due to multiple sclerosis in the U.S. rose between 1999 and 2020, a trend that was observed across both ...